RESUMEN
The acceptance of the WHO regimen in a group of 220 patients was approximately 84.5%. Only 11% abandoned the treatment, and the substitution of ethionamide or prothionamide for clofazimine due to excessive hyperpigmentation was necessary in only eight cases. The WHO regimens adopted provided a more frequent (monthly) relationship between the patients and their health service. It was necessary to: a) reorganize the technical-administrative infrastructure, with the intention of providing an improved service to the patients for treatment and control; and b) pay more attention to the problem of deformities and health education activities. As for the side effects of the drugs, 54 patients showed alterations in their liver function tests, which were usually mild and which resolved despite continuation of the treatment. Of the reactional episodes observed during MDT, it would not appear that the therapeutic regimens contributed to their occurrence or aggravation.
Asunto(s)
Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Adolescente , Adulto , Brasil , Clofazimina/administración & dosificación , Clofazimina/efectos adversos , Clofazimina/uso terapéutico , Dapsona/administración & dosificación , Dapsona/efectos adversos , Dapsona/uso terapéutico , Quimioterapia Combinada , Etionamida/administración & dosificación , Etionamida/uso terapéutico , Femenino , Humanos , Leprostáticos/administración & dosificación , Leprostáticos/efectos adversos , Masculino , Aceptación de la Atención de Salud , Cooperación del Paciente , Prednisolona/administración & dosificación , Prednisolona/uso terapéutico , Protionamida/administración & dosificación , Protionamida/uso terapéutico , Rifampin/administración & dosificación , Rifampin/uso terapéutico , Población UrbanaAsunto(s)
Leprostáticos/administración & dosificación , Lepra/tratamiento farmacológico , Tuberculosis/tratamiento farmacológico , Dapsona/administración & dosificación , Dapsona/uso terapéutico , Combinación de Medicamentos/administración & dosificación , Combinación de Medicamentos/uso terapéutico , Quimioterapia Combinada , Humanos , Isoniazida/administración & dosificación , Isoniazida/uso terapéutico , Leprostáticos/uso terapéutico , Paraguay , Protionamida/administración & dosificación , Protionamida/uso terapéutico , Rifampin/administración & dosificación , Rifampin/uso terapéuticoRESUMEN
From January 1980 to December 1984, 418 leprosy patients were treated in Guadeloupe with a daily multiple drug regimen using rifampin as an essential drug. The analysis of the data collected during this period of times gives the possibility of estimating the patient's approval, tolerance and attendance to this treatment. The approval is satisfactory in new cases of leprosy and in ancient cases relapsed under dapsone monotherapy but less in inactive ancient patients already treated with dapsone monotherapy. Attendance of the 418 patients to the multiple drug regimen is satisfactory too and similar to the attendance of patients treated with dapsone monotherapy in Guadeloupe and to the attendance of patients with monthly multiple drug regimen in another Caribbean country. Reactions did not occur with higher gravity or frequency than in patients under dapsone monotherapy. The high incidence of hepatitis (14%) due to the toxicity of protionamide in the combination rifampin-protionamide-dapsone make obligatory the monthly assessment of the liver functions in multibacillary patients treated with such a drug combination.